Market closedNon-fractional

Iovance Biotherapeutics/IOVA

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Ticker

IOVA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Carlos, United States

Employees

557

IOVA Metrics

BasicAdvanced
$2.2B
Market cap
-
P/E ratio
-$1.81
EPS
0.65
Beta
-
Dividend rate
$2.2B
0.65
4.633
4.283
10.778
12.407
-34.48%
-66.77%
1,007.95
3.18
5.6
-4.74
-23.77%
-0.67%

What the Analysts think about IOVA

Analyst Ratings

Majority rating from 14 analysts.
Buy

IOVA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-16,128.57% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$700K
75.00%
Net income
-$113M
-2.92%
Profit margin
-16,128.57%
-44.53%

IOVA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.46
-$0.45
-$0.42
-
Expected
-$0.80
-$0.45
-$0.43
-$0.42
-$0.34
Surprise
-40.99%
1.25%
4.28%
-0.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Iovance Biotherapeutics stock?

Iovance Biotherapeutics (IOVA) has a market cap of $2.2B as of July 05, 2024.

What is the P/E ratio for Iovance Biotherapeutics stock?

The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of July 05, 2024.

Does Iovance Biotherapeutics stock pay dividends?

No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Iovance Biotherapeutics dividend payment date?

Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Iovance Biotherapeutics?

Iovance Biotherapeutics (IOVA) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Iovance Biotherapeutics stock

Buy or sell Iovance Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing